Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 5.54
CYNO's Cash to Debt is ranked higher than
76% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.27 vs. CYNO: 5.54 )
CYNO' s 10-Year Cash to Debt Range
Min: 2.24   Max: No Debt
Current: 5.54

Equity to Asset 0.77
CYNO's Equity to Asset is ranked higher than
82% of the 453 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. CYNO: 0.77 )
CYNO' s 10-Year Equity to Asset Range
Min: 0.48   Max: 0.87
Current: 0.77

0.48
0.87
F-Score: 6
Z-Score: 4.85
M-Score: -2.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 7.57
CYNO's Operating margin (%) is ranked higher than
79% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 5.49 vs. CYNO: 7.57 )
CYNO' s 10-Year Operating margin (%) Range
Min: -27.9   Max: 15.75
Current: 7.57

-27.9
15.75
Net-margin (%) 5.59
CYNO's Net-margin (%) is ranked higher than
78% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. CYNO: 5.59 )
CYNO' s 10-Year Net-margin (%) Range
Min: -31.25   Max: 12.72
Current: 5.59

-31.25
12.72
ROE (%) 4.68
CYNO's ROE (%) is ranked higher than
72% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 5.07 vs. CYNO: 4.68 )
CYNO' s 10-Year ROE (%) Range
Min: -23.98   Max: 48.3
Current: 4.68

-23.98
48.3
ROA (%) 3.73
CYNO's ROA (%) is ranked higher than
76% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.61 vs. CYNO: 3.73 )
CYNO' s 10-Year ROA (%) Range
Min: -14.3   Max: 22.91
Current: 3.73

-14.3
22.91
ROC (Joel Greenblatt) (%) 24.83
CYNO's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 8.37 vs. CYNO: 24.83 )
CYNO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -62.49   Max: 60.47
Current: 24.83

-62.49
60.47
Revenue Growth (%) 21.90
CYNO's Revenue Growth (%) is ranked higher than
93% of the 339 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. CYNO: 21.90 )
CYNO' s 10-Year Revenue Growth (%) Range
Min: -13   Max: 24.8
Current: 21.9

-13
24.8
EBITDA Growth (%) 78.30
CYNO's EBITDA Growth (%) is ranked higher than
98% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. CYNO: 78.30 )
CYNO' s 10-Year EBITDA Growth (%) Range
Min: -74.3   Max: 86.6
Current: 78.3

-74.3
86.6
EPS Growth (%) -41.10
CYNO's EPS Growth (%) is ranked higher than
54% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. CYNO: -41.10 )
CYNO' s 10-Year EPS Growth (%) Range
Min: -41.1   Max: 210.1
Current: -41.1

-41.1
210.1
» CYNO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CYNO Guru Trades in Q4 2013

Chuck Royce 255,600 sh (+7000%)
Mario Gabelli 23,686 sh (unchged)
Paul Tudor Jones 239,100 sh (-33.03%)
Steven Cohen 252,100 sh (-45.95%)
» More
Q1 2014

CYNO Guru Trades in Q1 2014

Paul Tudor Jones 259,322 sh (+8.46%)
Steven Cohen Sold Out
Chuck Royce 253,500 sh (-0.82%)
Mario Gabelli 20,250 sh (-14.51%)
» More
Q2 2014

CYNO Guru Trades in Q2 2014

Jim Simons 32,271 sh (New)
Mario Gabelli 20,250 sh (unchged)
Chuck Royce 253,500 sh (unchged)
Paul Tudor Jones 14,666 sh (-94.34%)
» More
Q3 2014

CYNO Guru Trades in Q3 2014

Chuck Royce 256,500 sh (+1.18%)
Jim Simons Sold Out
Paul Tudor Jones 13,472 sh (-8.14%)
Mario Gabelli 13,828 sh (-31.71%)
» More
» Details

Insider Trades

Latest Guru Trades with CYNO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2014-09-30 Reduce -31.71%$18.94 - $23.5 $ 27.3924%13828
Mario Gabelli 2013-09-30 Reduce -71.03%0.01%$21.65 - $28.48 $ 27.3910%23686
Mario Gabelli 2013-06-30 Add 308.77%0.01%$23.12 - $27.37 $ 27.399%81753
Joel Greenblatt 2013-03-31 Sold Out 0.03%$24.11 - $29.85 $ 27.392%0
Joel Greenblatt 2012-12-31 New Buy0.03%$21.2 - $27.48 $ 27.3912%18472
Charles Brandes 2012-03-31 Sold Out 0.01%$12 - $19.28 $ 27.3991%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 39.40
CYNO's P/E(ttm) is ranked higher than
79% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 106.60 vs. CYNO: 39.40 )
CYNO' s 10-Year P/E(ttm) Range
Min: 5.41   Max: 670.43
Current: 39.4

5.41
670.43
P/B 1.80
CYNO's P/B is ranked higher than
85% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.78 vs. CYNO: 1.80 )
CYNO' s 10-Year P/B Range
Min: 0.46   Max: 4.96
Current: 1.8

0.46
4.96
P/S 2.20
CYNO's P/S is ranked higher than
77% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. CYNO: 2.20 )
CYNO' s 10-Year P/S Range
Min: 0.5   Max: 6.18
Current: 2.2

0.5
6.18
PFCF 28.90
CYNO's PFCF is ranked higher than
88% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CYNO: 28.90 )
CYNO' s 10-Year PFCF Range
Min: 8.7   Max: 164.91
Current: 28.9

8.7
164.91
EV-to-EBIT 24.82
CYNO's EV-to-EBIT is ranked higher than
81% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 73.45 vs. CYNO: 24.82 )
CYNO' s 10-Year EV-to-EBIT Range
Min: -183   Max: 311.7
Current: 24.82

-183
311.7
Current Ratio 3.16
CYNO's Current Ratio is ranked higher than
75% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. CYNO: 3.16 )
CYNO' s 10-Year Current Ratio Range
Min: 1.67   Max: 7.09
Current: 3.16

1.67
7.09
Quick Ratio 2.29
CYNO's Quick Ratio is ranked higher than
73% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. CYNO: 2.29 )
CYNO' s 10-Year Quick Ratio Range
Min: 0.87   Max: 5.83
Current: 2.29

0.87
5.83

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 11.84
CYNO's Price/Net Current Asset Value is ranked higher than
84% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CYNO: 11.84 )
CYNO' s 10-Year Price/Net Current Asset Value Range
Min: 1.06   Max: 9.16
Current: 11.84

1.06
9.16
Price/Tangible Book 3.43
CYNO's Price/Tangible Book is ranked higher than
80% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 6.57 vs. CYNO: 3.43 )
CYNO' s 10-Year Price/Tangible Book Range
Min: 0.56   Max: 4.58
Current: 3.43

0.56
4.58
Price/DCF (Projected) 1.81
CYNO's Price/DCF (Projected) is ranked higher than
90% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CYNO: 1.81 )
CYNO' s 10-Year Price/DCF (Projected) Range
Min: 1.05   Max: 2.09
Current: 1.81

1.05
2.09
Price/Median PS Value 1.07
CYNO's Price/Median PS Value is ranked higher than
78% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. CYNO: 1.07 )
CYNO' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 2.85
Current: 1.07

0.32
2.85
Price/Graham Number 2.42
CYNO's Price/Graham Number is ranked higher than
85% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CYNO: 2.42 )
CYNO' s 10-Year Price/Graham Number Range
Min: 0.65   Max: 7.95
Current: 2.42

0.65
7.95
Earnings Yield (Greenblatt) 4.00
CYNO's Earnings Yield (Greenblatt) is ranked higher than
81% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. CYNO: 4.00 )
CYNO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 1687.3
Current: 4

0.3
1687.3
Forward Rate of Return (Yacktman) 1.17
CYNO's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 349 Companies
in the Global Medical Devices industry.

( Industry Median: 0.59 vs. CYNO: 1.17 )
CYNO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.7   Max: 3.8
Current: 1.17

0.7
3.8

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:C9S.Germany
Cynosure Inc was incorporated in July 1991. The Company develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands. It has also developed an aesthetic treatment product for the home use market. The Company sells its products through a direct sales force in North America, France, Spain, the United Kingdom, Germany, Australia, Korea, China, Japan and Mexico and through international distributors in approximately 120 other countries. Its product portfolio is composed of various energy sources including Alexandrite, diode, Nd:YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light. It offers single energy source systems as well as workstations that incorporate two or more different types of lasers or pulsed light technologies. It offers multiple technologies and system alternatives at various price points depending mainly on the number and type of energy sources included in the system. Its products are designed to be easily upgradeable to add additional energy sources and handpieces, which provide its customers with technological flexibility as they expand their practices. The Company's latest innovations are SmartLipo system and PicoSure system. The Company's flagship products include Elite, Affirm/SmartSkin, Cynergy, Accolade. The Company sells its aesthetic treatment systems to the traditional physician customer base of dermatologists and plastic surgeons as well as to non-traditional physician customers who are providing aesthetic services using laser and light-based technology. Non-traditional physician customers can include primary care physicians, obstetricians and gynecologists. As of December 31, 2013, the Company owns over 60 United States patents, as well as many United States pending applications and foreign patents and pending applications. It is also joint owners with El.En. of certain patents and pending applications. The Company competes with Cutera, Solta Medical, Syneron Medical, ZELTIQ Aesthetics, Alma Lasers among others. Its products are medical devices subject to extensive and rigorous regulation by the U.S. Food and Drug Administration, or FDA, as well as other regulatory bodies.
» More Articles for CYNO

Headlines

Articles On GuruFocus.com
old newsletter Apr 10 2012 
Cynosure Reports Second Quarter 2009 Financial Results Jul 28 2009 
Cynosure Inc. (CYNO) CFO Timothy W Baker buys 2,500 Shares Feb 27 2009 
Cynosure Inc. (CYNO) CEO Michael R Davin buys 2,500 Shares Feb 27 2009 
Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 Feb 10 2009 
Cynosure: A Value Play on Vanity Jan 18 2009 

More From Other Websites
Cynosure Signs Exclusive Agreement to Market MonaLisa Touch™ in North America for Gynecology... Nov 18 2014
Cynosure Signs Exclusive Agreement to Market MonaLisa Touch™ in North America for Gynecology... Nov 18 2014
CYNOSURE INC Financials Nov 14 2014
10-Q for Cynosure, Inc. Nov 09 2014
CYNOSURE INC Files SEC form 8-K/A, Financial Statements and Exhibits Nov 07 2014
Cynosure (CYNO) Shares March Higher, Can It Continue? Oct 29 2014
Cynosure Inc Earnings Call scheduled for 9:00 am ET today Oct 28 2014
Cynosure Reports Record Third-Quarter Revenue of $71.5 Million, Up 18% Year-Over-Year Oct 28 2014
Cynosure posts 3Q profit Oct 28 2014
Cynosure posts 3Q profit Oct 28 2014
CYNOSURE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Oct 28 2014
Cynosure Reports Record Third-Quarter Revenue of $71.5 Million, Up 18% Year-Over-Year Oct 28 2014
Q3 2014 Cynosure Inc Earnings Release - Before Market Open Oct 28 2014
Cynosure To Host Third-Quarter 2014 Financial Results Conference Call On October 28 Oct 15 2014
Cynosure To Host Third-Quarter 2014 Financial Results Conference Call On October 28 Oct 15 2014
CYNOSURE INC Files SEC form 8-K, Other Events Oct 06 2014
Cynosure Receives Expanded FDA Clearance to Market PicoSure® for Treatment of Wrinkles Sep 24 2014
Cynosure Promotes Chris Aronson to Vice President of North American Sales Sep 10 2014
CYNOSURE INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Other Events,... Sep 08 2014
Cynosure Inc. Conference Call to discuss the Acquisition of Assets of RF Medical Device from Ellman... Sep 08 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK